Sen-Jam Pharmaceutical Appoints Dr. Ashley St. John to Advisory Board

Sen-Jam Pharmaceutical Welcomes Dr. Ashley St. John

Huntington, N.Y., March 11, 2025 – Sen-Jam Pharmaceutical proudly announces the addition of Dr. Ashley St. John, Ph.D., to its Scientific Advisory Board, further reinforcing its commitment to developing innovative therapies aimed at modulating inflammation. Dr. St. John is a distinguished Associate Professor at Duke-National University of Singapore (Duke-NUS) Medical School, where she also leads research at the Laboratory of Immunity and Immune Pathology.

Dr. St. John is an internationally recognized authority in the fields of immunology, host-pathogen interactions, and vaccine development. Her contributions to the scientific community are vast, with numerous publications in prestigious journals such as Nature Reviews Immunology, The Journal of Clinical Investigation, and Science Advances. Her research has significantly influenced current methodologies regarding immune modulation and inflammation management, focusing particularly on mast cell biology and viral immunity.

A key area of Dr. St. John's expertise lies in mucosal vaccine research and AI-driven drug discovery. These specializations are perfectly aligned with Sen-Jam Pharmaceutical's PAIRe (Pleiotropic Anti-Inflammatory Regulators) technology, which aims to target inflammation at its source and develop proactive therapeutic solutions.

Expressing her thoughts about this new collaboration, Dr. St. John stated, “I am thrilled to join Sen-Jam Pharmaceutical and contribute to their avant-garde approach in inflammation science. Their innovative strategies in immune modulation and drug development are incredibly timely, given the crucial role inflammation plays in a myriad of diseases today. I eagerly anticipate utilizing my knowledge in immunology and pathogen interactions to advance Sen-Jam's groundbreaking mission.”

Jim Iversen, CEO of Sen-Jam Pharmaceutical, acknowledged the importance of Dr. St. John’s contributions, stating, “Her unparalleled expertise in immunology and infectious disease research is invaluable for our company. As we progress with our primary assets—SJP-005, which addresses opioid withdrawal relief, and SJP-002C, aimed at viral respiratory infections—Dr. St. John’s guidance will be essential in fine-tuning our scientific and clinical strategies.”

Also echoing excitement about Dr. St. John's appointment, Jackie Iversen, Co-Founder and Chief Clinical Officer of Sen-Jam, remarked, “Ashley’s robust knowledge in immunology and infectious diseases makes her a tremendous asset to our advisory board. Her commitment to translating scientific advancements into practical solutions resonates deeply with our goal of delivering efficient and safe therapeutics to patients in need.”

The Sen-Jam family is eager to welcome Dr. St. John on board as they strive toward a future of innovative healthcare solutions.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is at the forefront of developing inflammation-modulating therapies with its PAIR technology, which seeks to prevent and mitigate inflammation more effectively than current treatments. Their diverse portfolio addresses various health issues like alcohol hangovers, viral respiratory infections, opioid withdrawal, and chronic inflammatory conditions, marking a shift from traditional reactive treatments to proactive healthcare strategies.